Liquid crystal nanoparticle formulation as an oral drug delivery system for liver-specific distribution

• Main Authors: Lee DR, Park JS, Bae IH, Lee Y, Kim BM
• Format: Article
• Language: English
• Published: Dove Medical Press 2016-03-01
• Series: International Journal of Nanomedicine
• Subjects: LCNP; PIT; Sustained release; Bioavailability
• Online Access: https://www.dovepress.com/liquid-crystal-nanoparticle-formulation-as-an-oral-drug-delivery-syste-peer-reviewed-article-IJN

Dong Ryeol Lee,1,2 Ji Su Park,1 Il Hak Bae,1 Yan Lee,1 B Moon Kim1 1Department of Chemistry, College of Natural Sciences, Seoul National University, Seoul, Republic of Korea; 2Technology Development Center, BASF Company Ltd., Hwaseong, Gyeonggi-do, Republic of Korea Abstract: Liquid crystal nanoparticles have been utilized as an efficient tool for drug delivery with enhanced bioavailability, drug stability, and targeted drug delivery. However, the high energy requirements and the high cost of the liquid crystal preparation have been obstacles to their widespread use in the pharmaceutical industry. In this study, we prepared liquid crystal nanoparticles using a phase-inversion temperature method, which is a uniquely low energy process. Particles prepared with the above method were estimated to be ~100 nm in size and exhibited a lamellar liquid crystal structure with orthorhombic lateral packing. Pharmacokinetic and tissue distribution studies of a hydrophobic peptide-based drug candidate formulated with the liquid crystal nanoparticles showed a five-fold enhancement of bioavailability, sustained release, and liver-specific drug delivery compared to a host–guest complex formulation. Keywords: LCNP, PIT, sustained release, bioavailability